CYB004

CYB004 is Cybin's deuterated DMT analog, a short-acting psychedelic in Phase 2a testing for generalized anxiety disorder [1]. The trial (NCT06051721) finished enrollment at 36 participants and is comparing inhaled CYB004 against placebo, with the Hamilton Anxiety Rating Scale (HAM-A) as the primary efficacy measure [1]. DMT is the active ingredient in ayahuasca and produces an intense but very short trip when inhaled or injected, typically 15-30 minutes versus the 4-6 hours of a psilocybin session. Cybin's bet is that deuteration (placing heavier deuterium atoms at metabolically labile positions to slow enzymatic breakdown) extends the half-life enough to produce a more predictable, clinic-friendly dosing window. The commercial logic is simple: shorter sessions mean lower per-patient delivery costs and higher clinic throughput than the day-long psilocybin model. The readout (Cybin guides Q1 2026) will land in a GAD market where MindMed's lysergide candidate MM-120 already showed a strong Phase 2b signal, with a 7.6-point placebo-corrected HAM-A reduction at week 4 in the 100 µg arm, setting a credible competitive bar [2].

Novel compound, never approved anywhere. The Phase 2a trial is listed as active, not recruiting, meaning all 36 patients have been dosed and the company is waiting on data lock [1]. No FDA designations (breakthrough therapy, fast track, orphan, RMAT) have been disclosed for CYB004 in GAD. Cybin's lead program is actually CYB003, a deuterated psilocybin analog, which is in the Phase 3 APPROACH/PARADIGM program for major depressive disorder with FDA breakthrough therapy designation; CYB004 is the second-priority asset behind it [3]. Cybin acquired the CYB004 program from Small Pharma (the SPL028 inhaled DMT asset) and inherited the prior Phase 1 work in healthy volunteers; published reporting from that Phase 1 work indicates the inhaled formulation was generally well tolerated with no serious adverse events and produced the intended short-duration psychedelic experience, though Cybin has not disclosed dose-by-dose PK in its public materials [3]. Topline readout from NCT06051721 is guided for Q1 2026 [3]. If the GAD signal is positive, the natural next step is a Phase 2b dose-ranging study, not a direct jump to Phase 3, given the small n=36 sample and exploratory design. Cybin trades on the NYSE American (ticker CYBN); its financing runway is discussed in the risks section below.

DMT (N,N-dimethyltryptamine) is a small molecule that binds to and activates the 5-HT2A receptor, a serotonin receptor sitting on the surface of cortical neurons, especially layer 5 pyramidal cells in the prefrontal cortex. When 5-HT2A is activated, those neurons change how they integrate signals, firing patterns across the cortex become more variable, and the brain enters the altered state characteristic of a psychedelic experience [4]. The 5-HT2A target is well-validated as the mediator of psychedelic effects: blocking it with ketanserin abolishes the trip from LSD, psilocybin, and DMT [4]. Whether that subjective experience is required for therapeutic benefit, or whether it is a side effect of the actual anxiolytic mechanism, is still actively debated. The leading alternative hypothesis is synaptic remodeling: psychedelics trigger release of brain-derived neurotrophic factor (BDNF), a protein that drives growth and strengthening of synaptic connections. BDNF binds to its receptor TrkB, and the resulting signaling cascade is thought to physically rewire the cortical circuits that encode fear and rumination. If that plasticity mechanism is the real driver of the durable anxiety reduction seen in trials like MM-120, then the subjective trip is a side effect rather than the cure, and non-hallucinogenic 5-HT2A or TrkB-biased analogs become a viable program design. The investment relevance is large: a non-hallucinogenic successor would shed the in-clinic monitoring overhead that gates this whole class. Deuteration is the trick that distinguishes CYB004 from plain DMT. Normal DMT is oxidatively deaminated almost instantly by monoamine oxidase (MAO), the enzyme that degrades serotonin and similar molecules. Substituting deuterium at a metabolically labile position creates stronger carbon-deuterium bonds at the site MAO attacks, slowing the deamination step and extending the half-life via a kinetic isotope effect [5]. Cybin has not publicly disclosed the exact positions of deuterium substitution in CYB004, so the specific structural details remain proprietary. The therapeutic case for the target in anxiety leans heavily on the MM-120 (LSD) Phase 2b result in GAD, where a single 100 µg dose produced a 7.6-point placebo-corrected HAM-A reduction at week 4 (LSMD -21.3 vs -13.7, p=0.0004) that persisted to week 12 [2]. For context: HAM-A is a 14-item clinician-rated scale that ranges from 0 to 56, and a minimum clinically important difference is generally cited at roughly 3-5 points, so the MM-120 effect was both statistically robust and well above the clinical-meaningfulness threshold. That outside positive read is the strongest reason to take a 5-HT2A program in GAD seriously.

NCT06051721 is a Phase 2a proof-of-concept study sponsored by Cybin IRL Limited, the Irish subsidiary that holds the company's psychedelic IP [1]. Enrollment target was 36 patients with generalized anxiety disorder, and the trial is now active, not recruiting [1]. The primary endpoint is change in HAM-A, a 14-item clinician-administered measure (range 0-56) that has been the regulatory standard for anxiety drug approvals going back to the original benzodiazepines, with an MCID of approximately 3-5 points. The drug is delivered by inhalation, which is the route Cybin selected to get a fast-onset, controlled-duration session; Cybin has not publicly itemized the specific doses being tested in the Phase 2a arms in its registry posting or press releases, so dose-by-arm interpretation will have to wait for the topline release [1]. At n=36, the study is statistically underpowered to deliver a definitive efficacy verdict; its real job is to show a clean safety profile, confirm the inhaled pharmacokinetics behave as designed, and produce a HAM-A effect size large enough to justify a properly powered Phase 2b. The lack of an active comparator (such as an SSRI or buspirone) means any positive result will only support the case against placebo, not against current standard of care. That is fine for a proof-of-concept but means the trial cannot, on its own, support a label.

Our model estimates a 3% chance this drug is eventually approved. That starting point comes from the historical approval rate for Phase 2 drugs in this area, which is about 24%. The estimate is pulled down from there by several factors: heavier-than-usual blinding, the sponsor's thin or weak approval record, weak earlier-phase results, and a randomized design. The remaining factors are close to average for this stage, so they don't move the number much.

Efficacy risk is the dominant near-term concern. The trial is small (n=36) and uses a subjective clinician-rated outcome (HAM-A) in a disease with a documented large placebo response, so even a true drug effect can be masked or amplified by chance. The patient population is broad GAD without a biomarker for selection, meaning responders and non-responders are mixed together in a small sample. There is no validated biomarker for psychedelic-responsive anxiety. Safety risk centers on two issues. First, 5-HT2B receptor cross-reactivity has been the on-target liability for serotonergic drugs (the cardiac valvulopathy that pulled fenfluramine from the diet-drug market was 5-HT2B-mediated), and any psychedelic program has to demonstrate clean cardiac safety with repeat dosing [7]. Second, the acute psychological effects (anxiety, dissociation, occasional panic during the session) are well known with DMT and could produce dropouts and a high adverse event rate during the dosing visit. Execution risk is the psychedelic-specific overhead: every dosing session needs a trained monitor in a controlled clinical setting, which limits how fast a Phase 2b/3 program can enroll and pushes the per-patient cost well above a standard psychiatric trial. Financing risk is the explicit gate on CYB004's timeline. After Cybin's $175M registered direct offering in October 2025, the company reported a pro forma cash position of approximately $248M, with a quarterly net loss of roughly $33.7M as of the September 30, 2025 quarter, implying roughly 21-22 months of runway centered on funding the CYB003 Phase 3 program through expected end-of-2026 readouts [3]. CYB004 sits inside that envelope but is not the primary capital priority; any Phase 2b expansion will likely require fresh financing. Commercial risk, even with a positive Phase 2a and eventual approval, is real. Payers will require a REMS-style restricted distribution program (the model FDA built for Spravato/esketamine), and reimbursement for the in-clinic session time has been the rate-limiter on Spravato uptake [8]. Cybin will also have to compete with MM-120, which received FDA breakthrough therapy designation in GAD and entered its Phase 3 program in 2024-2025, putting MindMed plausibly ahead of CYB004 to any future NDA filing in this indication by at least a year [2].

Worth watching, but not the lead Cybin story. The lead is CYB003 (psilocybin analog) in Phase 3 for MDD, which is where the company's value is concentrated, with topline guidance for Q4 2026 [3]. CYB004 in GAD is a smaller bet that gains importance only if the Phase 2a HAM-A delta is large and clean, or if the inhaled dosing profile turns out to be commercially attractive (much shorter clinic visit than psilocybin). The specific data point to watch is the placebo-corrected HAM-A change from baseline at the primary timepoint. MM-120's 100 µg arm delivered a 7.6-point placebo-corrected LSMD at week 4 [2]; any CYB004 result that lands meaningfully below that, with a smaller n, will be hard to spin as competitive given that MM-120 is roughly a year ahead in the regulatory pathway. Conversely, a placebo-corrected delta in the same range or better, even on small numbers, would be a clear go-signal for a properly powered Phase 2b. A positive signal would justify that Phase 2b dose-ranging program, likely funded by a partnership or follow-on equity raise since the existing runway is earmarked for CYB003. A negative signal would probably mean Cybin deprioritizes CYB004 to focus all capital on CYB003. Check back on the Q1 2026 topline. Until then, the more material catalyst for Cybin shareholders is the CYB003 Phase 3 MDD readout later in 2026.